 Connection
Mario Enrico Canonico to Hypoglycemic Agents
This is a "connection" page, showing publications Mario Enrico Canonico has written about Hypoglycemic Agents.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.593 |
|
|
|
-
Canonico ME, Hsia J, Masoudi FA, Bosworth HB, Greene S, Batch BC, Hamilton N, de Araujo TB, Jackson M, Broussard M, Gooden Z, Guthrie NL, Hansell B, Matteliano-Madu L, Mosesso K, Berman MA, Bonaca MP. Digital Therapeutic Based Randomized Investigation to Improve Glycemic Control in Patients With Type 2 Diabetes and Residual Hyperglycemia on Stable Medical Therapy: Rationale, Design, and Baseline Characteristics of the BRIGHT Trial. J Am Heart Assoc. 2025 Aug 05; 14(15):e038737.
Score: 0.458
-
Canonico ME, Hess CN, Rogers RK, Bonaca MP. Medical Therapy for Peripheral Artery Disease. Curr Cardiol Rep. 2024 Jun; 26(6):651-659.
Score: 0.105
-
Busti M, Canonico ME, Keramida K, Palazzuoli A, Kato E, Sakata Y, Alexy T, Grupper A, Nodari S, Ojji DB, Sverdlov AL, Guimaraes PO, Musella F, Ambrosy AP, Girerd N, Monzo L. Tirzepatide versus dulaglutide in heart failure: another SURPASS attempt yielding a tie. Heart Fail Rev. 2026 04 15; 31(1).
Score: 0.030
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|